← boardnext 2026-09-15next 2026-09-19
TEVA
Teva Branded Pharmaceutical Products R&D LLCdistress 0/10 · well-funded / low risk$30.20+0%today-17% from 52w high
tevapharm.com31,173 employeesFounded 1901Tel Aviv-Yafo, IsraelDrug Manufacturers - Specialty & Generic
Lead: Multiple System Atrophy
Revenue
$3982M
Liquidity
$3741M
Runway
—
Shares 1y
+2%
Price & events
-4.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.2%
1D
-6.3%
1W
-9.1%
1M
-3.2%
3M
-5.1%
6M
+82.1%
1Y
+78.2%
2Y
+242.8%
5Y
+192.1%
All
Overview
- Market Cap
- $35.17B
- Volume
- 277.03K
- 52 Week Range
- $15.38 – $36.34
- Total Shares
- 1.16B
- Float Shares
- 1.08B
- Short %
- 2.77%
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 62.40%
- RVOL
- 0.05x
- Beta
- 0.86
Pipeline stages · 2 programs
TEV-56278, Pembrolizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Fp/ABS, FP, ABS
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 6 trials · 6 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09-15 Estimated 50% readout ~2026-10-30 | Phase 2 | TEV-53408 | Celiac Disease | — | active not recruiting |
| 2026-09-19 Estimated 50% readout ~2026-12-03 | Phase 3 | Fp/ABS, FP, ABS | Asthma | — | recruiting |
| 2026-10-31 Estimated 50% readout ~2027-01-14 | Phase 3 | TEV-56248, Albuterol sulfate | Asthma | — | active not recruiting |
| 2027-09-15 Estimated 50% readout ~2027-10-30 | Phase 2 | TEV-56286 | Multiple System Atrophy | — | recruiting |
| 2029-05-03 Estimated 50% readout ~2029-06-17 | Phase 2 | TEV-56286 | Multiple System Atrophy | — | recruiting |
Show all 6 trials · 1 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2029-05-26 Estimated 50% readout ~2029-06-25 | Phase 1 | TEV-56278, Pembrolizumab | Advanced Solid Tumors | — | recruiting |
Catalyst news & presentations · 1
- 2026-07-29earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 1,164,426,972 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $41 (+35% upside) · 10 analysts
- 2026-05-06BarclaysOverweight
- 2026-04-30JP MorganOverweight
- 2026-04-30Piper SandlerOverweight
- 2026-04-30Truist SecuritiesBuy
- 2026-04-30UBSBuy
- 2026-04-09B of A SecuritiesBuy
Competitors — Multiple System Atrophy
Recent news
- 2026-07-23Militia Capital Management LLC Takes $3.50 Million Position in Teva Pharmaceutical Industries Ltd. $TEVA - MarketBeat
- 2026-07-22Hsbc Holdings PLC Has $28.79 Million Holdings in Teva Pharmaceutical Industries Ltd. $TEVA - MarketBeat
- 2026-07-22Teva Pharmaceutical Industries (TEVA) Projected to Post Earnings on Wednesday - MarketBeat
- 2026-07-2277,800 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Acquired by Barometer Capital Management Inc. - MarketBeat
- 2026-07-21Swiss National Bank Buys 941,700 Shares of Teva Pharmaceutical Industries Ltd. $TEVA - MarketBeat
- 2026-07-21Jennison Associates LLC Has $43.35 Million Position in Teva Pharmaceutical Industries Ltd. $TEVA - MarketBeat
- 2026-07-20A Look at Teva Pharmaceutical Industries Ltd (TEVA) After 3.2% D - GuruFocus
- 2026-07-20A Look at Teva Pharmaceutical Industries Ltd (TEVA) After 3.2% D - GuruFocus
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.